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Abstract
Introduction: Matrix metalloproteinases are produced by tumour cells, hence, they may be associated with 
tumour progression including invasion, migration, angiogenesis and metastasis. Finding prognostic markers 
to better identify patients with higher risk for poor survival would be valuable in order to customize pre- and 
postoperative treatment as well as to enable closer follow-up of these patients. Aim of our study was to ex-
amine MMP-2, MMP-7 and MMP-9 serum levels and correlated them with pathological data such as stage of 
the colorectal cancer (CRC) and outcome. 
Methods: The investigation included 82 patients with operable CRC without distant metastases, who had 
underwent blood tests in order to determine the MMP-2, MMP-7 and MMP-9 serum levels in the following 
time periods: preoperatively, 3, 6, 9 and 12 months postoperatively. 
Results: The values of the investigated MMPs decrease postoperatively and start to increase 6 month later 
in patients of all stages of the disease, reaching the highest value 12 month postoperatively with statistically 
important differences of MMP-2, MMP-7 and MMP-7 serum levels in terms of disease staging and defi ned 
points of time. Analysis of the results showed that the MMP-2 serum levels obtained 3 and 12 months post-
operatively, than MMP-7 serum levels 12 months postoperatively and the MMP-9 serum levels in all analyzed 
points in time were in signifi cant association with the CRC patients’outcome.
Conclusion: The MMP-2, MMP-7 and especially MMP-9 serum values could be important indicators for 
diagnosis of the patients with CRC and for monitoring of disease progression.
 © 2012 All rights reserved
Keywords: colorectal cancer, matrix metalloproteinases, staging, prognosis.
Serum Matrix Metalloproteinase-2, -7 and -9 
(MMP-2, MMP-7, MMP-9) levels as Prognostic 
Markers in Patients with Colorectal Cancer
Elena Kostova1*, Maja Slaninka-Miceska1, Nikola Labacevski1, Krume Jakjovski1, Jasmina Trojacanec1, 
Emilija Atanasovska1, Vlado Janevski2, Redzep Selmani2, Gordana Petrushevska3, Vesna Janevska3
1 Department of Preclinical and Clinical Pharmacology and Toxicology, Faculty of Medicine, Ss. Cyril and Methodius University, 
50 Divizija bb, 1000 Skopje, Republic of Macedonia. 2 Digestive Surgery Clinic, Faculty of Medicine, Ss. Cyril and Methodius 
University, Skopje, R. Macedonia. 3 Department of Pathology, Faculty of Medicine, Ss. Cyril and Methodius University, 1000 
Skopje, Republic of Macedonia.
Introduction
Th e degradation of extracellular matrix (ECM) 
is a crucial step in tumour progression, aggres-
sive growth and metastases. Th e invasion of 
cancer cells within the basement membrane de-
pends on matrix metalloproteinases (MMPs) 
and their inhibition activities (1). MMPs are a 
family of extracellular structurally related zinc-
dependent endoproteases capable of degrad-
ing all the ECM components. At present, 23 
members of the human MMP gene family are 
known. Based on their structure and substrate 
specifi city, MMPs are classifi ed into subgroups 
of collagenases, stromelysins and stromelysin-
like MMPs, matrilysins, gelatinases, membrane-
type MMPs (MT-MMPs) and other MMPs (1). 
MMPs play an important role in the physiologic 
degradation of ECM, e.g., in tissue morphogenesis, 
tissue repair and angiogenesis. MMPs have also 
important functions in pathologic conditions char-
acterized by excessive degradation of ECM, such 
as rheumatoid arthritis, osteoarthritis, periodon-
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titis, autoimmune blistering disorders of the skin 
and in tumour invasion and metastasis. MMPs are 
produced by tumour cells; hence, they may be as-
sociated with tumour progression including inva-
sion, migration, angiogenesis and metastasis (2, 3). 
Among the MMPs, matrix metalloproteinase 
2 (MMP-2) and matrix metalloproteinase 9 
(MMP-9), as members of gelatinases, plays im-
portant roles in the migration of malignant cells, 
because of their ability to degrade type IV col-
lagen (4). Th e mechanisms of activation of these 
enzymes are diff erent. MMP-9 modulates per-
meability of the vascular endothelium, whereas 
MMP-2 promotes cleavage of extracellular ma-
trix proteins and is intensively expressed by tu-
mour and stromal components of cancer (5).
Matrix metalloproteinase 7 (MMP-7) or matrily-
sin, as a member of stromelysins is able to induce 
cell apoptotic impairment. Matrilysin can regulate 
angiogenesis either by inducing a direct prolif-
erative eff ect on vascular endothelial cells or pro-
ducing angiogenesis inhibitors (angiostatin, end-
ostatin and neostatin-7) or by enriching the variety 
of angiogenesis mediators, such as the soluble 
vascular endothelial growth factor (sVEGF) (6). 
Increased levels of matrix metalloproteinase 
in tumour tissues or in blood circulation have 
been found to correlate with many cancers, in-
cluding colorectal cancer (CRC). Several pre-
vious studies have shown that MMPs may 
play an important role as an indicator for ap-
pearance of CRC and its progression (7, 8, 9). 
Colorectal cancer (CRC) is a common disease 
and it is one of the leading causes of cancer re-
lated deaths in developed countries (10). Despite 
improvements in surgical techniques, adjuvant 
and neo-adjuvant chemotherapy, the 5-year sur-
vival rate in patients with CRC ranges from 5-90% 
with tumour progression (stages: I: 90-95%, II: 
75-85%, III: 50-60% and IV: 0-10%). Th e prog-
nosis in patients without distant metastasis varies 
from 50-95% depending on the tumour stage (11). 
Th e correct staging of each CRC patient is crucial 
in order to plan an optimal treatment regimen. It 
is widely recognised that prognostic information 
based on clinical and histopathological investi-
gation is insuffi  cient, although tumour stage and 
lymph node involvement are the main prognostic 
tools in evaluating cancer specifi c survival. It is 
questionable to expose a large number of patients 
to adjuvant treatment with considerable side ef-
fects without indications that they will benefi t 
from such treatment. Finding prognostic mark-
ers to better identify patients with higher risk for 
poor survival (12, 13) would be valuable in order 
to customise pre- and postoperative treatment as 
well as to enable closer follow-up of these patients.
In our study, we examined MMP-2, MMP-
7 and MMP-9 serum levels and correlated 
them with pathological data such as stage 
of the disease and the patients ‘outcome.
Methods
Th e study included a total of 82 previously un-
treated CRC patients, 30 (36.58%) females and 
52 (63.41) males (aged 43 to 75 years, mean age 
of 67.85; SD±9.67) with operable CRC, with-
out detectable distant metastases, who respect-
ed the medical instructions and were avail-
able for follow-up. All patients underwent a 
surgical resection of the primary neoplasm at 
the University Clinic for Abdominal Surgery 
in Skopje in the period of 2 years (2007-2009). 
Blood samples from all patients were drawn be-
fore surgical treatment, as well as 3, 6, 9, and 
12 months postoperatively in order to exam-
ine MMP-2, MMP-7 and MMP-9 serum lev-
els. None of the CRC patients had received che-
motherapy before blood sample collection. To 
standardize clotting conditions, all sera were 
separated within 1 h aft er blood collection, 
aliquoted and stored at −80°C until assayed. 
Serum levels of MMP-2, MMP-7 and MMP-
9 were determined using a quantitative solid 
phase sandwich enzyme-linked immunosorbent 
assay (ELISA) (R&D Systems, USA) accord-
ing to the manufacturer's instructions. MMP-2, 
MMP-7 and MMP-9 technique can detect both 
pro- and active forms of recombinant human 
MMP-2, MMP-7 and MMP-9. High concentra-
tions of MMP-2, MMP-7 and MMP-9 were di-
luted with calibrator, to produce samples with 
values within the dynamic range of the assay.
Th e surgically removed specimens were histo-
pathologically analyzed at the Institute of Pathol-
ogy of the Faculty of Medicine, Skopje, where 
the pathological stage was defi ned for every 
patient according to the International Union 
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against Cancer (UICC-pTNM) and Ameri-
can Joint Committee on Cancer (AJCC) 2010. 
Forty-three patients with stage II B and III (A,B,C) 
received adjuvant chemotherapy at the Insti-
tute for Radiotherapy and Oncology in Skopje. 
Correlations were made between the MMPs 
serum levels and the pathological parameters.
Statistical analysis
Descriptive statistics (mean) are given accord-
ing to normality of the distribution. Normality of 
the distribution was determined by Kolmogorov-
Smirnov’s test. Analysis of variance with Kruskall-
Wallis test was fi rst used in the analysis of diff erent 
sample types. In the case of signifi cant results, the 
analyses were continued by pairing the variables 
and analysing them with Mann-Whitney’s U-test. 
Fisher’s exact probability test and Pearson’s Chi-
Square test (r) were used for testing the associa-
tion (linearity of the correlation of serum concen-
trations) between MMPs and major prognostic 
variables in CRC, such as grade and stage. P-values 
less than 0.05 (p<0.05) were considered as statisti-
cally signifi cant.
Results
Th ere have been 17 (20.73%) patients in stage I of 
the disease, 40 (48.78%) patients in stage II and 
25 (30,48%) patients in stage III. Lymph node 
metastases were substantiated in 25 (30.48%) 
patients and were not found in 57 (69.51%) 
patients with diff erent pT category (Table 1).
Th e majority of patients were with pT-
3N0M0 (26.82%), i.e. patients in stage II A 
of the disease, and the smallest number of 
patients were with pT4aN1M0 (4.87%), 
i.e. patients in stage III B of the disease.
Th e mean MMP-2, MMP-7 and MMP-9 serum lev-
els in terms of disease staging and defi ned points 
of time are shown in Table 2, Figure 1 and Figure 2.
Th e mean MMP-2 serum levels shown in Table 1 
and Figure 1, in patients with stage I of the disease, 
decreased aft er the operation and started slightly to 
increase aft er the 3th month postoperatively. Th is 
might be due to the 6 patients with poor outcome in 
FIGURE 1.  Mean MMP-2 and MMP-9 (ng/mL) serum values in terms of disease staging and defi ned points of time
Stage pTNM Number of patients (n=82) %
I pT1 N0 M0 pT2 N0 M0
8
9 20.73
II pT3 N0 M0 pT4a N0 M0
22
18 48.78
III
pT3 N1b M0 
pT3 N2a M0 
pT4a N1b M0 
pT4a N2b M0
7
9
4
5
30.48
TABLE 1.  Staging of the disease in CRC patients according 
to AJCC
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this group, with mean survival time of 28.5 months. 
Th e obtained MMP-2 mean serum levels of the pa-
tients in stage II of the disease goes very similarly 
to the mean serum levels of patients in stage I and 
reaches the peak in the 12th month postoperative-
ly; that may be due to the 19 out of 40 patients with 
poor outcome, with mean survival of 26.66 months.
Th e mean levels of MMP-2 in patients in stage III of 
the disease, decreased aft er tumour resection, in-
creased abruptly aft er the 3 months postoperative-
ly and continued to increase slightly aft er 6 months 
postoperatively. Th is might be due to the poor out-
come of more than half of the patients, 18 out of 25 
patients with mean survival time of 21.8 months. 
Th ere was a signifi cant diff erence between the 
mean MMP-2 serum levels before tumour resec-
tion and aft er the operation, i.e. between the pre-
operative and postoperative levels during defi ned 
control points of time in all encompassed CRC 
stages. Th ere was a signifi cant diff erence of the 
MMP-2 serum levels among the stages (p<0.05).
Th e mean MMP-7 serum levels are separately 
shown in Figure 2, and they show a similar ten-
dency of postoperative decreasing and perma-
nent increasing aft er the 3 months, especially 
in stage III. We did not fi nd a signifi cant diff er-
ence between the MMP-7 serum levels in stage 
I and stage II during each control points in time, 
but there was a signifi cant diff erence between 
the MMP-7 serum levels from stage I and II 
in terms of stage III (p<0.05). Th ere was a sig-
nifi cant diff erence between preoperative and 
postoperative MMP-7 serum levels (p<0.05).
Th ere were signifi cant diff erences between 
MMP-9 serum levels in all stages (p<0.01), as 
well as between preoperative and postopera-
tive serum levels in all defi ned points of time.
Th e number of patients who received che-
motherapy and the outcome of all included 
patients in the study are shown in Table 3.
We found signifi cant diff erences in terms of 
Stage
MMP-2 (ng/mL) MMP-7 (ng/mL) MMP-9 (ng/mL)
I II III I II III I II III
Preoperatively 117.62 147.96 169.72 4.04 4.66 5.38 259.03 313.35 384.34
3 months postoperat. 104.85 137.5 154.38 3.38 3.6 3.86 234 249.31 307.54
6 months postoperat. 117.33 162.45 231.9 3.92 5.37 7.42 298.63 358.143 576.86
9 months postoperat. 126.99 186 252 4.76 7.15 9.96 329.43 429.83 717.11
12 months postoperat. 140.73 223.34 271.51 5.14 8 12.24 341.11 521.65 846.45
TABLE 2.  Mean serum levels of MMP-2, MMP-7 and MMP-9 (ng/mL) in terms of disease staging and defi ned points of time
Stage 
N=82
With 
chemotherapy %
Without 
chemotherapy %
Poor 
outcome %
Stage I / / 17 20.73 6 7.31
Stage II A / / 22 26.82 8 9.75
Stage II B 18 21.95 / / 11 13.41
Stage III B 20 24.39 / / 15 18.29
Stage III C 5 6.09 / / 3 3.65
Total 43 52.43 39 47.56 43 52.43
TABLE 3.  Patients with different stage of the disease who received chemotherapy and the outcome of the disease
FIGURE 2.  Mean MMP-7 (ng/mL) serum levels in terms of 
disease staging and defi ned points of time
173JOURNAL OF HEALTH SCIENCES 2012; 2 (3)
ELENA KOSTOVA ET AL.: SERUM MATRIX METALLOPROTEINASE-2, -7 AND -9 (MMP-2, MMP-7, MMP-
9) LEVELS AS PROGNOSTIC MARKERS IN PATIENTS WITH COLORECTAL CANCER
the poor outcome in the CRC patients be-
tween stage I and stage II B (p<0.05), be-
tween stage I and stage III (p<0.01), as well 
as between stage II A and stage III (p<0.01).
Associations of the examined parameters and poor 
outcome are shown in Table 4, where it is shown 
that MMP-2 serum levels preoperatively, at 3 and 
12 months postoperatively, are in a signifi cant cor-
relation with the lethal outcome of the CRC pa-
tients, than MMP-7 serum levels preoperatively 
and at 12 months, as well as MMP-9 preopera-
tively and at 3, 9 and 12 months postoperatively.
Discussion 
MMP-2 is a collagenase discovered for the fi rst 
time in metastatic murine tumours and in cul-
tured human melanoma cells. It is secreted by 
fi broblasts, endothelial cells, osteoblasts, kerato-
cytes, macrophages and many malignant cells (14).
MMP-2 is expressed in numerous normal tis-
sues as the lungs, heart, kidneys, placenta, and 
the muscles. MMP-2 is synthesized and secreted 
as an inactive proenzyme, while as an active en-
zyme it degrades the type-IV collagen as well as 
the type I, V, VII and X, the laminin, the elastin, 
the fi bronectin and the proteoglycans (15, 16).
MMP-7 (matrilysin) is a proteolytic enzyme, 
which is expressed in glandular and ductal epi-
thelium of many tissues. It degrades type IV and 
X collagen, the elastin, the fi bronectin, the lam-
inin, the osteopontin, the proteoglycans, as well 
as numerous other substrates. MMP-7 is also 
synthesized and secreted by cancer cells as an 
inactive proenzyme. Aft er the activation, the 
MMP-7 is found in soluble active form or bound 
to the membrane of the tumour epithelium 
cells, which has also a proteolitic capability (17).
MMP-9 was discovered for the fi rst time as an 
elastin binding protein, which is synthesized 
by the macrophages and the polymorphonucle-
ars. In normal conditions, MMP-9 is expressed 
only in several cell types as trophoblasts, osteo-
clasts, leukocytes, and dendritic cells. It is also 
being expressed by several types of tumours, in 
the tumour cells and in the stromal cells. MMP-
9 also degrades the components of the ECM, es-
pecially type IV, V, VII, X, XI, XIV collagen, fi -
bronectin, elastin, osteonectin and entactin (18).
Diverse results have been obtained from numer-
ous examinations which have been made in or-
der to determine the signifi cance of the MMPs 
in the diagnosing of malignancies and to deter-
mine their infl uence on the disease outcome (19).
In 1998, in order to determine the active and inactive 
MMP-2 and MMP-9 expression, Pearsons, Warson, 
Collins, et al. examined 53 colorectal carcinomas, 
15 colorectal adenomas and 15 gastric carcinomas. 
Th ey found out overexpression of the two enzymes 
in both the colorectal and gastric carcinomas (20).
Th e aim of the examination conducted by Tuton, 
George, Eccles, et al. was to determine the MMP-
2 and MMP-9 distribution in CRC patients and 
to compare the levels of the two enzymes in pa-
tients' plasma and the changes that occur in the 
plasma aft er the resection. Th ey wanted to dis-
cover whether plasma levels are a refl ection of 
the clinical staging and the development of the 
disease. Th eir results showed that MMP-2 plasma 
levels were considerably elevated in patients with 
CRC; they considerably decreased aft er surgical 
resection of the tumour, and MMP-9 serum lev-
els were considerably elevated in all stages of the 
disease in CRC patients, while they decreased 
aft er the surgical resection of the neoplasm (21).
On the contrary, the Ruokolainen’s investiga-
tion for the prognostic role of the MMP-2 and 
Parameter P r
Stage <0.01 0.635
pT <0.05 0.331
pN <0.05 0.618
MMP-2 preoperatively <0.01 0.156
MMP-2 3 months postoperat. <0.05 0.793
MMP-2 6 m postoperatively NS /
MMP-2 9 m postoperatively NS /
MMP-2 12 m postoperatively <0.01 0.548
MMP-7 preoperatively <0.05 0.391
MMP-7 3 m postoperatively NS /
MMP-7 6 m postoperatively NS /
MMP-7 9 m postoperatively NS /
MMP-7 12 m postoperatively <0.05 0.728
MMP-9 preoperatively <0.01 0.619
MMP-9 3 m postoperatively <0.01 0.351
MMP-9 6 m postoperatively NS /
MMP-9 9 m postoperatively <0.01 0.219
MMP-9 12 m postoperatively <0.01 0.416
TABLE 4.  Statistically signifi cant correlations with poor out-
come in CRC patients 
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MMP-9 and their tissue inhibitors (TIMP-1 
and TIMP-2) in squamous head and neck can-
cer, showed that serum MMP-2 immunoreac-
tive protein levels in healthy patients were higher 
than those in patients with cancer, while the 
MMP-9 and TIMP-1 levels were considerably 
higher in patients with squamous carcinoma. 
Th e authors determined an important correla-
tion between the serum levels of MMP-9 and 
TIMP-1 with immunohistochemical expression 
of MMP-9 and TIMP-1 from tumour tissue (22).
Dragutinovic, Radonjic, Petronijevic, et al. in their 
study of 32 CRC patients and another 11 controls 
using immunohistochemistry and serum values 
of CEA, CA 19-9 and MMP-2 and 9 reported an 
important correlation of the MMP levels with 
the staging, but not with the CEA and CA 19-9 
serum levels. Th ey concluded that the serum 
MMP-2 and MMP-9 detection can be a useful 
tool for identifi cation of the CRC patients (23).
Maurel, Nadal, Garcia-Albeniz et al. examined the 
MMP-7 serum levels in 87 healthy patients and 
in 120 CRC patients in order to determine the se-
rum level prognostic signifi cance of this enzyme. 
Th ey found out that patients with advanced can-
cer had considerably higher mean MMP-7 levels 
in comparison with those without metastases and 
in comparison with healthy subjects. Th ey discov-
ered a signifi cant correlation between the MMP-7 
levels and shorter survival time, which led them 
to the conclusion that the elevated MMP-7 se-
rum levels are an independent prognostic factor 
for survival in patients with advanced CRC (24).
We have observed (unpublished data) that in CRC 
patients with low MMP-7 but high LDH levels, 
MMP-7 values can increase during chemotherapy 
treatment, and would be therefore implicated in 
early acquired resistance, aft er initial response. 
Th erefore, we speculate that MMP-7 would be 
implicated in primary chemoresistance in the sub-
group of patients with well-known poor prognosis, 
to an even more aggressive phenotype, or both.
Leelawat, Sakchinabut, Narog, and Wannaprasert 
analyzing the CEA, CA 19.9, MMP-7 and MMP-9 
serum levels in patients with cholangiocarcinoma 
detected that only MMP-7 level was considerably 
higher in patients with cancer (25). Levels of to-
tal MMP-7 can be measured in human serum and 
it is feasible using a simple ELISA technique, as 
this has been recently shown in few other studies.
Serum measurements of total MMP-2, MMP-7 
and MMP-9 can be considered as an indirect es-
timation of tumour MMP-2, MMP-7 and MMP-9 
expression. Other techniques, such as zymography, 
are useful to distinguish between activated MMP-
2, MMP-7, MMP-9 and pro-forms and might be 
implemented in the near future for further analysis.
Conclusion
In our examination, we have determined that 
the MMP-2, MMP-7 and MMP-9 serum levels 
decrease considerably aft er the resection of the 
primary neoplasm, as well as the MMP-2 serum 
levels at 3th and 12th month postoperatively, than 
MMP-7 serum levels preoperatively and at 12th 
month and the MMP-9 serum levels at 3th, 9th 
and 12th month postoperatively are in correla-
tion with the poor outcome of the CRC patients. 
Subsequently, detection of serum MMP-2, MMP-7 
and MMP-9 is feasible and done through a non-
invasive technique. Th ey could be potential serum 
markers which may be useful in the CRC detec-
tion and in monitoring of the disease progression.
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